论文部分内容阅读
肝肾综合征(HRS)是与进行性肝脏疾病有关的功能性肾功能受损。其肾功能受损可以表现为可逆性的急性、亚急性或进行性肾小球滤过率(GFR)下降。 HRS一词在医学中应用已50多年,对其发病机理的研究较多。但迄今未完全明确,故临床治疗HRS也具有较大的困难。近年来有关本征发病机量的研究在某些方面有所突破,在此作一简述,以期对临床实践工作有所帮助。一、心房利钠因子的作用 1981年DeBold从大鼠心房肌中提取了具有利钠利尿作用的物质,现称为心房利钠因子(ANF)
Hepatorenal syndrome (HRS) is a functional impairment of renal function associated with progressive liver disease. Impaired renal function may manifest as a reversible reduction in acute, subacute, or progressive glomerular filtration rate (GFR). The term HRS has been used in medicine for more than 50 years, and its pathogenesis has been studied more. But so far not entirely clear, so the clinical treatment of HRS also has greater difficulties. In recent years, the research on intrinsic pathogenesis has made some breakthroughs in some aspects, and makes a brief introduction here in the hope of helping clinical practice. First, the role of atrial natriuretic factor In 1981 DeBold extracted from the rat atrial muscle with Natriuretic effect of substance, now known as atrial natriuretic factor (ANF)